These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
383 related articles for article (PubMed ID: 36945020)
1. Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority randomized controlled trial. Zhou T; Gong Y; Li J; Wang Y; Wang X Trials; 2023 Mar; 24(1):209. PubMed ID: 36945020 [TBL] [Abstract][Full Text] [Related]
2. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial. Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541 [TBL] [Abstract][Full Text] [Related]
3. Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial. Li Y; Li J; Wang B; Jing Q; Zeng Y; Hou A; Wang Z; Liu A; Zhang J; Zhang Y; Zhang P; Jiang D; Liu B; Fan J; Zhang J; Li L; Su G; Yang M; Jiang W; Qu P; Zeng H; Li L; Qiu M; Ru L; Chen S; Zhou Y; Qiao S; Stone GW; Angiolillo DJ; Han Y; JAMA Cardiol; 2024 Jun; 9(6):523-531. PubMed ID: 38630489 [TBL] [Abstract][Full Text] [Related]
4. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. Ge Z; Kan J; Gao X; Raza A; Zhang JJ; Mohydin BS; Gao F; Shao Y; Wang Y; Zeng H; Li F; Khan HS; Mengal N; Cong H; Wang M; Chen L; Wei Y; Chen F; Stone GW; Chen SL; Lancet; 2024 May; 403(10439):1866-1878. PubMed ID: 38599220 [TBL] [Abstract][Full Text] [Related]
5. Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial. Wu H; Xu L; Zhao X; Zhang H; Cheng K; Wang X; Chen M; Li G; Huang J; Lan J; Wei G; Zhang C; Wang Y; Qian J; Ge J; Circulation; 2023 Jan; 147(3):212-222. PubMed ID: 36335890 [TBL] [Abstract][Full Text] [Related]
6. The safety and efficacy of indobufen or aspirin combined with clopidogrel in patients with acute myocardial infarction after percutaneous coronary intervention. Dai WB; Ren JY; Hu ST; Zhang YK; Gu TS; Wu X; Zhang JK; Che JJ; Ma XH; Liu T; Li GP; Chen KY Platelets; 2024 Dec; 35(1):2364748. PubMed ID: 39115322 [TBL] [Abstract][Full Text] [Related]
7. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638 [TBL] [Abstract][Full Text] [Related]
8. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. Cannon CP; Gropper S; Bhatt DL; Ellis SG; Kimura T; Lip GY; Steg PG; Ten Berg JM; Manassie J; Kreuzer J; Blatchford J; Massaro JM; Brueckmann M; Ferreiros Ripoll E; Oldgren J; Hohnloser SH; Clin Cardiol; 2016 Oct; 39(10):555-564. PubMed ID: 27565018 [TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials. Li J; Wang Q; Wu C; Qu X; Zhang L; He X; Ma S; Qiu M; Wang X Cardiology; 2023; 148(4):363-373. PubMed ID: 37094558 [TBL] [Abstract][Full Text] [Related]
10. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial. Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085 [TBL] [Abstract][Full Text] [Related]
11. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. Hahn JY; Song YB; Oh JH; Chun WJ; Park YH; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC; JAMA; 2019 Jun; 321(24):2428-2437. PubMed ID: 31237645 [TBL] [Abstract][Full Text] [Related]
12. Guanxinning tablet for patients who switch from dual antiplatelet therapy to aspirin alone after percutaneous coronary intervention: study protocol for a cluster randomized controlled trial. Li J; Ju J; Chen Z; Liu J; Lu F; Gao R; Xu H Trials; 2018 Feb; 19(1):93. PubMed ID: 29415754 [TBL] [Abstract][Full Text] [Related]
13. Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial. Song YB; Oh SK; Oh JH; Im ES; Cho DK; Cho BR; Lee JY; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC; Hahn JY Am Heart J; 2018 Mar; 197():77-84. PubMed ID: 29447787 [TBL] [Abstract][Full Text] [Related]
14. Temporary omission of oral anticoagulation in atrial fibrillation patients undergoing percutaneous coronary intervention: rationale and design of the WOEST-3 randomised trial. Verburg A; Bor WL; Küçük IT; Henriques JPS; Vink MA; Ruifrok WT; Plomp J; Heestermans TACM; Schotborgh CE; Vlaar PJ; Magro M; Rikken SAOF; van den Broek WWA; van Mieghem CAG; Cornelis K; Rosseel L; Dujardin KS; Vandeloo B; Vandendriessche T; Ferdinande B; van 't Hof AWJ; Tijssen JGP; Limbruno U; De Caterina R; Rubboli A; Angiolillo DJ; Adriaenssens T; Dewilde W; Ten Berg JM EuroIntervention; 2024 Jul; 20(14):e898-e904. PubMed ID: 39007830 [TBL] [Abstract][Full Text] [Related]
15. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial. Zheng YY; Wu TT; Yang Y; Hou XG; Gao Y; Chen Y; Yang YN; Li XM; Ma X; Ma YT; Xie X Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):211-221. PubMed ID: 31603191 [TBL] [Abstract][Full Text] [Related]
16. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. Oldgren J; Steg PG; Hohnloser SH; Lip GYH; Kimura T; Nordaby M; Brueckmann M; Kleine E; Ten Berg JM; Bhatt DL; Cannon CP Eur Heart J; 2019 May; 40(19):1553-1562. PubMed ID: 30793734 [TBL] [Abstract][Full Text] [Related]
17. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Hahn JY; Song YB; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Kim J; Choi KH; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Gwon HC; Lancet; 2018 Mar; 391(10127):1274-1284. PubMed ID: 29544699 [TBL] [Abstract][Full Text] [Related]
18. Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial. Li Y; Jing Q; Wang B; Wang X; Li J; Qiao S; Chen S; Angiolillo DJ; Han Y Am Heart J; 2020 Oct; 228():1-7. PubMed ID: 32739652 [TBL] [Abstract][Full Text] [Related]
19. Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial. Baos S; Underwood W; Culliford L; Reeves BC; Rogers CA; Bowles R; Johnson T; Baumbach A; Mumford A Trials; 2017 Nov; 18(1):529. PubMed ID: 29121979 [TBL] [Abstract][Full Text] [Related]
20. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T; JAMA; 2019 Jun; 321(24):2414-2427. PubMed ID: 31237644 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]